美股A股
StockGist
Back
10-K2026-02-17· deepseek-chat

MED · Medifast, Inc.

0001628280-26-008656

SEC filing

Summary

Medifast, Inc. reported a challenging fiscal year 2025 with revenue of $385.8 million. The company generated a gross profit of $275.2 million, representing a gross margin of 71.3%. However, selling, general, and administrative expenses of $289.4 million resulted in an operating loss of $14.2 million. Total other income of $8.6 million, primarily from interest income of $5.5 million, partially offset the operating loss, leading to a loss before income taxes of $5.6 million. After an income tax expense of $13.0 million, the company reported a net loss of $18.7 million, or a loss per share of $2.00 (basic and diluted). Despite the net loss, operating activities generated positive cash flow of $6.9 million. The company ended the year with total assets of $248.0 million, including $89.3 million in cash and cash equivalents, and maintained a strong equity position of $198.9 million against total liabilities of $49.1 million.

Key takeaways

Full analysis

Performance Summary

Medifast, Inc. reported a net loss of $18.7 million for fiscal year 2025, compared to the prior year's performance which is not provided in the data. Revenue for the period was $385.8 million, generating gross profit of $275.2 million. The company experienced an operating loss of $14.2 million due to selling, general, and administrative expenses of $289.4 million exceeding gross profit. Other income of $8.6 million, including $5.5 million in interest income, partially offset the operating loss, resulting in a loss before income taxes of $5.6 million. The company recorded an income tax expense of $13.0 million, contributing to the net loss position. Basic and diluted loss per share was $2.00, based on approximately 11.0 million weighted average shares outstanding.

Revenue Analysis

The filing does not provide segment breakdown, geographic mix, or specific growth drivers for revenue. The total revenue reported was $385.8 million for fiscal year 2025. No comparative data from prior periods is provided in the available information to analyze revenue trends or growth patterns. The document does not disclose revenue by business segment, product category, or geographic region.

Margins & Profitability

The company achieved a gross margin of 71.3% for fiscal year 2025, calculated from gross profit of $275.2 million on revenue of $385.8 million. The operating margin was negative 3.7%, resulting from the operating loss of $14.2 million. Selling, general, and administrative expenses represented 75.0% of revenue, which exceeded the gross profit margin. Cost of sales was $110.6 million, representing 28.7% of revenue. The net loss margin was 4.8% of revenue.

Cash Flow & Balance Sheet

Operating activities generated positive cash flow of $6.9 million despite the net loss of $18.7 million, supported by non-cash adjustments including depreciation and amortization of $14.2 million and share-based compensation of $7.6 million. Investing activities used $7.9 million primarily for purchases of investment securities ($84.4 million) and property and equipment ($5.6 million), partially offset by proceeds from sale and maturities of investment securities ($82.1 million). Financing activities used $0.6 million mainly for cash dividends paid to stockholders ($0.2 million) and net shares repurchased for employee taxes ($0.4 million). Free cash flow, calculated as operating cash flow ($6.9 million) minus capital expenditures ($5.6 million), was $1.3 million. The company ended the period with $89.3 million in cash and cash equivalents, total assets of $248.0 million, and total liabilities of $49.1 million, resulting in stockholders' equity of $198.9 million.

Outlook

The filing does not provide management guidance, strategic priorities, or specific risk factors in the available document content. No forward-looking statements or outlook information is included in the provided financial data and document text.